Table 1.

Patients characteristics.

Number of patients	138
Male/Female	92/46
Age at diagnosis (years)	3–75 (36)
Age at surgery (years)	15–79 (46)
Time between diagnosis and surgery (months)	1–471 (63)
Indication for intervention (patients):
Severe UC	17
Chronic resistant UC	91
Dysplasia or cancer	21
Fulminant UC	7
Clinical diagnosis (patients):
UC	127
IC	11
Preoperative clinical / endoscopic manifestations
Perianal abscesses	7
Anal fistulas	4
Hemorrhoids	6
Fissures	1
Backwash ileitis and ileal inflammation over 3 cm	2
Discontinuous inflammation (skip lesions)	4
Rectal sparing	4
Preoperative medical therapy (more than one per patients is possible)
None	2
Topical	10
Steroids	13
Azathioprine	53
Salazopyrine	2
Cyclosporine	8
Infliximab	73
Retuximab	1
Adalimumab	21
Golimumab	5
Edolizumab	2
Apheresis	1
Duration of therapy (months)	6 days–187 months
Preoperative symptoms
Pain at diagnosis	45
No. stool / day	1–40 (9)
>3 stool / day	94
Rectorrhagia	69
Fever	22
Weight loss	32
Perianal pain	8
Extraintestinal manifestations:
Joint manifestations (arthritis / ankylosing spondylitis)	12 (7/5)
Primary sclerosing cholangitis	4
Cutaneous manifestations (Pyoderma gangrenous/erythema nodosum)	4 (1/3)
Eyes involvement (uveitis/episcleritis)	1 (1/0)

 Data are shown as median (IQR) or frequency, as appropriate.